Hcw biologics reports fourth quarter 2023 and fiscal year end financial results and business highlights

Miramar, fla., april 01, 2024 (globe newswire) -- hcw biologics inc. (the “company” or “hcw biologics”) (nasdaq: hcwb), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended december 31, 2023.
HCWB Ratings Summary
HCWB Quant Ranking